Shares of Applied Genetic Technologies Corporation (NASDAQ:AGTC) have been assigned a consensus rating of “Hold” from the nine ratings firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $11.71.

Several brokerages recently issued reports on AGTC. Stifel Nicolaus reduced their price target on shares of Applied Genetic Technologies Corporation from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, September 14th. HC Wainwright set a $16.00 price target on shares of Applied Genetic Technologies Corporation and gave the stock a “buy” rating in a research report on Thursday, August 10th. ValuEngine downgraded shares of Applied Genetic Technologies Corporation from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. BMO Capital Markets reiterated an “outperform” rating and set a $7.00 price target (down previously from $14.00) on shares of Applied Genetic Technologies Corporation in a research report on Thursday, September 14th. Finally, Cantor Fitzgerald reduced their price target on shares of Applied Genetic Technologies Corporation from $15.00 to $9.00 and set a “neutral” rating on the stock in a research report on Thursday, September 14th.

Large investors have recently made changes to their positions in the business. Trexquant Investment LP raised its holdings in Applied Genetic Technologies Corporation by 3.2% during the 2nd quarter. Trexquant Investment LP now owns 20,000 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 611 shares during the last quarter. Nine Chapters Capital Management LLC bought a new stake in shares of Applied Genetic Technologies Corporation in the 3rd quarter valued at about $113,000. Wells Fargo & Company MN increased its stake in shares of Applied Genetic Technologies Corporation by 1.1% in the 1st quarter. Wells Fargo & Company MN now owns 19,005 shares of the biotechnology company’s stock valued at $131,000 after acquiring an additional 200 shares during the last quarter. Virtu KCG Holdings LLC bought a new stake in shares of Applied Genetic Technologies Corporation in the 2nd quarter valued at about $178,000. Finally, Credit Suisse AG increased its stake in shares of Applied Genetic Technologies Corporation by 10.9% in the 1st quarter. Credit Suisse AG now owns 27,110 shares of the biotechnology company’s stock valued at $187,000 after acquiring an additional 2,662 shares during the last quarter. 54.79% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/applied-genetic-technologies-corporation-agtc-receives-average-recommendation-of-hold-from-analysts/1686030.html.

Shares of Applied Genetic Technologies Corporation (NASDAQ AGTC) traded down $0.03 during midday trading on Thursday, reaching $3.43. The company’s stock had a trading volume of 85,744 shares, compared to its average volume of 128,859. Applied Genetic Technologies Corporation has a fifty-two week low of $3.25 and a fifty-two week high of $10.85. The company has a market cap of $61.06, a price-to-earnings ratio of 42.50 and a beta of 1.56.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last issued its earnings results on Wednesday, September 13th. The biotechnology company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.40). The firm had revenue of $8.30 million during the quarter, compared to analyst estimates of $12.39 million. Applied Genetic Technologies Corporation had a net margin of 4.28% and a return on equity of 1.45%. The firm’s revenue for the quarter was down 31.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.15 EPS. equities analysts anticipate that Applied Genetic Technologies Corporation will post -0.81 earnings per share for the current fiscal year.

About Applied Genetic Technologies Corporation

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Analyst Recommendations for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.